Twentyeight-Seven
Latest round
- Series A
Last raised
- May 2019
Total raised
- $40M
Investors
- 8
About Twentyeight-Seven
Twentyeight-Seven, Inc.Founded in 2016, Twentyeight-Seven, Inc. is headquartered in Watertown, US. The company specializes in developing therapeutics that address RNA and DNA processes.Twentyeight-Seven, Inc. develops small-molecule therapeutics aimed at addressing dysregulated nucleic acid processes such as RNA and DNA. Their products target cellular mechanisms that control homeostasis, metabolism, differentiation, and responses to stimuli, focusing on serious diseases including cancer and autoimmune disorders. By aiming to influence multiple oncogenic pathways, their therapeutics seek to overcome limitations associated with traditional therapies that typically target single pathways.The revenue model for Twentyeight-Seven, Inc. is centered on the development and commercialization of their therapeutic products. Revenue is likely generated through partnerships with pharmaceutical firms for clinical trials and distribution agreements, along with potential direct sales to healthcare providers upon product launch. While specific pricing structures remain undisclosed, the focus on small-molecule drugs suggests alignment with industry-standard pricing models.00 mn, Twentyeight-Seven, Inc. plans to utilize these funds to advance the development of their therapeutics targeting dysregulated nucleic acids. The company is focusing on launching new products designed to address complex diseases and exploring expansion into additional markets, including further penetration into the United States and European healthcare sectors. Details on specific product launch timelines and market entry strategies are to be determined as they progress.
Who invested in Twentyeight-Seven
8 investors across 2 rounds
See all investors in Twentyeight-Seven
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Twentyeight-Seven
Who invested in Twentyeight-Seven?
Twentyeight-Seven has 8 investors on record across 2 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Twentyeight-Seven raised?
Twentyeight-Seven has raised 2 venture rounds. Sign up free to see how much each round raised and the total.
When did Twentyeight-Seven last raise money?
Twentyeight-Seven's most recent round on record is a Series A, in May 2019.
What does Twentyeight-Seven do?
Twentyeight-Seven is a biotechnology company.
Where is Twentyeight-Seven headquartered?
Twentyeight-Seven is headquartered in Watertown, US.
Which VCs invest in companies like Twentyeight-Seven?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back biotechnology companies at Twentyeight-Seven's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series A
Raising like Twentyeight-Seven? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.